Security key
36254L308
- Security type / class
- Equity / Common Stock
- Total 13F shares
- 483,011
- Total 13F value
- $373,734
- Share change
- +113,802
- SEC-reported price per share
- $0.79
- Number of holders
- 38
- Value change
- +$113,728
- Number of buys
- 27
- Number of sells
- 12
- Shares outstanding
- 3,148,458
Holder snapshot
6 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q4 2025
Institutions
38
Top holders
10
GTBP full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q1 2026
Previous quarter: Q3 2025
GT Biopharma, Inc. SEC filings
GT Biopharma, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 36254L308
Recent filing periods:
Ownership snapshot
Top reported holders of GTBP - GT Biopharma, Inc. - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Five Narrow Lane LP
Disclosed value leader
Five Narrow Lane LP
Comparable rows
15/15
Latest evidence
30 Sep 2025
13D/G
13F
Lead comparable stake: 10%
13D/G row: Five Narrow Lane LP
Showing 1-6 of 15 holder rows.
Quick read
Five Narrow Lane LP leads the comparable SEC ownership view at 10%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Five Narrow Lane LP's linked filing trail.
Comparable ownership
Top 5
Five Narrow Lane LP
10%
CYTOVANCE BIOLOGICS INC
9.8%
BRISTOL INVESTMENT FUND LTD
2.4%
DRW Securities, LLC
4.5%
BANK OF MONTREAL /CAN/
2.9%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Five Narrow Lane LP |
13D/G
|
10%
|
$552,386
253,388 shares
|
$0 | 13 May 2025 |
| CYTOVANCE BIOLOGICS INC |
13D/G
|
9.8%
|
$478,416
219,457 shares
|
$0 | 30 Sep 2024 |
| BRISTOL INVESTMENT FUND LTD |
13D/G
|
2.4%
|
$171,405
74,524 shares
|
$0 | 29 May 2025 |
| DRW Securities, LLC |
13F
Company
|
4.5%
|
$83,505
142,380 shares
|
— | 30 Sep 2025 |
| BANK OF MONTREAL /CAN/ |
13F
Company
|
2.9%
|
$54,593
92,530 shares
|
— | 30 Sep 2025 |
| CITADEL ADVISORS LLC |
13F
Company
|
1.3%
|
$23,562
39,633 shares
|
— | 30 Sep 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q4 2025
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
38
Shares
483,011
Rows available
38
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q4 2025 vs Q3 2025 Across Filers
Q3 2025 holders
20
Q4 2025 holders
38
Holder diff
18
| Investor | Q3 2025 Shares | Q4 2025 Shares | Share Diff | Share Chg % | Q3 2025 value | Q4 2025 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend